1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Nippon Shokubai Announces Shares Acquisition of Lilac Pharma

11 Dec 2024
Admin
News Article

Nippon Shokubai Announces Shares Acquisition of Lilac Pharma

NIPPON SHOKUBAI CO., LTD. has announced to acquire all shares of Lilac pharma Inc. to make Lilac pharma a 100% subsidiary on December 9, 2024.

In cosmetics and pharmaceuticals, lipid nanoparticles like liposomes※1 have been drawing increasing attention as an innovative material from the point of contributing to the stability and permeability of the contained active ingredients.

Lilac pharma which is a Hokkaido University-initiated startup, is developing its business based on lipid nanoparticle manufacturing technology focusing on the size of lipid nanoparticles. Their own “iLiNP®️ Microfluidic Device

2 is different from conventional method, can continuously produce high-quality lipid nanoparticles of uniformsize easily. Furthermore, since the size can be controlled widely, iLiNP®️※2 is expected to be a technology for manufacturing highly functional lipid nanoparticles and is being provided for cosmetics and pharmaceuticals.

In 2017, Nippon Shokubai established the Cosmetics Business Division (at that time, the Cosmetics Business Planning Office) to promote the development of cosmetic ingredients utilizing its products and technologies, and to acquire ingredients and formulation technologies through business collaboration. Currently, Nippon Shokubai has a lineup of more than 15 cosmetic ingredients.

Also the Health & Medical business Division has established synthesis and analysis technologies for middle- molecular APIs, and is developing CDMO business for oligonucleotides and peptides.

Nippon Shokubai and Lilac pharma have successfully developed liposomes※1 for cosmetics with characteristics such as extremely high stability through joint research since 2019.

By making Lilac pharma a 100% subsidiary, Nippon Shokubai will accelerate the development efficiency of liposomes※1 and the establishment of a stable supply system, and aim to further expand its cosmetics and nanoparticle business for pharmaceuticals by utilizing the expertise in various fields.

A liposome is a 20 - 200 nm spherical vesicle having at least one lipid bilayer. The liposomes can improve stability and permeability into human skin by internally sealing unstable materials.
iLiNP®️ Microfluidic Device is the core technology of Lilac pharma which has obtained an exclusive patent license from Hokkaido University.
iLiNP®️ is a registered trademark of Lilac pharma

Name Lilac pharma Inc.

Headquarter Room #C, Hokkaido Collaboration Center (Collabo Hokkaido)
Kita 21, Nishi 12, Kita-Ward, Sapporo, Hokkaido 001-0021,Japan

About NIPPON SHOKUBAI CO., LTD.: Nippon Shokubai utilizes the unique technology to manufacture chemicals such as ethylene oxide, acrylic acids, catalysts, superabsorbent polymers. We use chemistry to make the impossible possible, and offer unprecedented solutions to the world, specifically in Environment & Energy, Electronics & Imaging and Daily Use fields. Our corporate mission is ""TechnoAmenity: Providing prosperity and comfort to people and society with our unique technology